ZAMUDIO, Spain--(BUSINESS WIRE)--Proteomika, a subsidiary of Personalised Medicine leader Progenika Biopharma SA, announced today an option agreement with Auguron Biosciences, Inc, giving them rights to exclusive access in two autoimmune disease areas to use Auguron’s Nucleic Acid Programmable Protein Array (NAPPA) technology.
